{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T05:06:58Z","timestamp":1774933618182,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.14219\/jada.archive.2011.0220","type":"journal-article","created":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T21:18:47Z","timestamp":1389215927000},"page":"506-513","source":"Crossref","is-referenced-by-count":28,"title":["Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab"],"prefix":"10.1016","volume":"142","author":[{"given":"Filippo","family":"Francini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Pascucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatora Tindara","family":"Miano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Bargagli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grazia","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Petrioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.14219\/jada.archive.2011.0220_bib1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.1992.10.4.591","article-title":"Treatment of bone metastases with dichloromethylene bisphosphonate","volume":"10","author":"Francini","year":"1992","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.14219\/jada.archive.2011.0220_bib2","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/annonc\/mdm442","article-title":"Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel","volume":"19","author":"Aapro","year":"2008","journal-title":"Ann Oncol"},{"issue":"9","key":"10.14219\/jada.archive.2011.0220_bib3","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaw: a growing epidemic","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"10.14219\/jada.archive.2011.0220_bib4","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"10.14219\/jada.archive.2011.0220_bib5","first-page":"99","article-title":"Osteonecrosis of the jaw and bisphosphonates (published correction appears in N Engl J Med 2005;353[25]:2728)","volume":"353","author":"Maerevoet","year":"2005","journal-title":"N Engl J Med"},{"issue":"9","key":"10.14219\/jada.archive.2011.0220_bib6","first-page":"1053","article-title":"Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates","volume":"20","author":"Van Poznak","year":"2006","journal-title":"Oncology (Williston Park)"},{"issue":"10","key":"10.14219\/jada.archive.2011.0220_bib7","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Systematic review: bisphosphonates and osteonecrosis of the jaws (published correction appears in Ann Intern Med 2006;145[3]:235)","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.14219\/jada.archive.2011.0220_bib8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s00520-010-0882-1","article-title":"A systematic review of bisphosphonate osteonecrosis (BON) in cancer","volume":"18","author":"Migliorati","year":"2010","journal-title":"Support Care Cancer"},{"issue":"34","key":"10.14219\/jada.archive.2011.0220_bib9","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.14219\/jada.archive.2011.0220_bib10","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"issue":"suppl","key":"10.14219\/jada.archive.2011.0220_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/BF03026321","article-title":"The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib","volume":"23","author":"Mashiba","year":"2005","journal-title":"J Bone Miner Metab"},{"issue":"5","key":"10.14219\/jada.archive.2011.0220_bib12","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.joms.2005.01.010","article-title":"Bisphosphonate osteochemonecrosis (bisphossy jaw): is this phossy jaw of the 21st century?","volume":"63","author":"Hellstein","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"issue":"22","key":"10.14219\/jada.archive.2011.0220_bib13","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"issue":"12","key":"10.14219\/jada.archive.2011.0220_bib14","first-page":"1658","article-title":"Managing the care of patients with bisphosphonate-associated osteonecrosis: an American Academy of Oral Medicine position paper (published correction appears in)","volume":"136","author":"Migliorati","year":"2005","journal-title":"JADA"},{"issue":"4","key":"10.14219\/jada.archive.2011.0220_bib15","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1586\/14737140.7.4.433","article-title":"Bevacizumab in the management of solid tumors","volume":"7","author":"Pa\u00f1ares","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"10.14219\/jada.archive.2011.0220_bib16","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"issue":"22 pt 1","key":"10.14219\/jada.archive.2011.0220_bib17","doi-asserted-by":"crossref","first-page":"6850","DOI":"10.1158\/1078-0432.CCR-07-4036","article-title":"Zoledronic acid and angiogenesis","volume":"13","author":"Ferretti","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.14219\/jada.archive.2011.0220_bib18","first-page":"1375","article-title":"Randomized phase II clinical trials","volume":"69","author":"Simon","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"10.14219\/jada.archive.2011.0220_bib19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"issue":"7","key":"10.14219\/jada.archive.2011.0220_bib20","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.14219\/jada.archive.2011.0220_bib21","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.14219\/jada.archive.2011.0220_bib22","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1002\/1097-0142(20010915)92:6<1468::AID-CNCR1471>3.0.CO;2-S","article-title":"Urinary calcium excretion in the monitoring of bone metastases from prostatic carcinoma","volume":"92","author":"Francini","year":"2001","journal-title":"Cancer"},{"issue":"1","key":"10.14219\/jada.archive.2011.0220_bib23","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"issue":"8","key":"10.14219\/jada.archive.2011.0220_bib24","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1634\/theoncologist.2008-0091","article-title":"Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy","volume":"13","author":"Estilo","year":"2008","journal-title":"Oncologist"},{"issue":"3","key":"10.14219\/jada.archive.2011.0220_bib25","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"issue":"2","key":"10.14219\/jada.archive.2011.0220_bib26","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1080\/07357900802208608","article-title":"Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents","volume":"27","author":"Aragon-Ching","year":"2009","journal-title":"Cancer Invest"},{"issue":"4","key":"10.14219\/jada.archive.2011.0220_bib27","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate and other risk factors associated with osteonecrosis of the jaw in cancer patients: a case-control study","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg"}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714620092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817714620092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T22:13:41Z","timestamp":1565043221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817714620092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0002817714620092"],"URL":"https:\/\/doi.org\/10.14219\/jada.archive.2011.0220","relation":{},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}